ArticleAngewandte Chemie (International ed. in English)2026
Light-Controlled Modulation of 15-Lipoxygenase-1 Regulates Intestinal Inflammatory Signaling.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Photopharmacology offers powerful opportunities for the spatiotemporal control of biological processes, yet the rational design of photoswitchable enzyme inhibitors remains challenging. Here, we report a target-guided strategy for the development of diazo-based photoswitchable inhibitors of human 15-lipoxygenase-1 (15-LOX-1), a key enzyme in inflammatory signaling, ferroptosis, and cancer. Guided by the structural features of known ligands, we developed three complementary photoswitch classes: reversible azobenzenes (ABs), azo-heteroarenes (HAs), and covalent azo-bis-alkynes (BAs). These compounds exhibit efficient E/Z photoisomerization and high bistability, supported by single-crystal x-ray diffraction and density functional theory calculations. Enzymatic inhibitory and kinetic studies revealed distinct activity and selectivity profiles within the tested substrates/isoenzyme: AB and HA derivatives function as E-ON/Z-OFF inhibitors, whereas BA derivatives display Z-ON/E-OFF behavior, enabling programmable light-controlled modulation. We validated 15-LOX-1 as a therapeutic target in cellular and in vivo mouse models of colonic inflammation, where inhibition suppressed IL-8 expression. Finally, using our reversible and covalent photoswitches, we demonstrate photoisomer-dependent suppression of IL-8. Beyond 15-LOX-1, this work establishes a generalizable framework for the rational development of selective photoswitchable inhibitors with tunable biological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.